Summary: In a small randomised, double-blind, three-period crossover pharmacokinetic study of 31 adults with type 2 diabetes, combining insulin icodec and semaglutide into the once-weekly fixed-ratio product IcoSema left icodec exposure and semaglutide total exposure essentially unchanged, but roughly doubled the semaglutide peak concentration (Cmax ratio 1.99, 90% CI 1.84 to 2.15) and shifted its peak markedly earlier (12 versus 84 hours). This is a single-dose pharmacokinetic finding, not evidence of glycaemic benefit.
PICO Summary
| Element | Detail |
|---|---|
| Population | 31 adults with type 2 diabetes (18 to 64 years, body weight 80 to 120 kg, HbA1c 6.0 to 8.5%); randomised, double-blind, three-period crossover single-dose pharmacokinetic study (NCT03789578); manufacturer-sponsored (Novo Nordisk). |
| Intervention | Single subcutaneous injection of IcoSema, a fixed-ratio combination of insulin icodec 175 U and semaglutide 0.5 mg; pharmacokinetic sampling to 840 hours post-dose (each participant crossed through all three arms with 6 to 9 weeks washout). |
| Comparison | Single subcutaneous injection of insulin icodec 175 U alone, or semaglutide 0.5 mg alone (same 31 participants, within-subject crossover comparison). |
| Outcome | Icodec pharmacokinetics unaffected by combination: IcoSema/icodec AUC ratio 1.06 (90% CI 1.01 to 1.12) and Cmax 1.12 (1.06 to 1.18), both within the 0.80 to 1.25 bioequivalence margin. Semaglutide AUC also unaffected: 1.11 (1.05 to 1.17). However, semaglutide Cmax was substantially higher with IcoSema: ratio 1.99 (90% CI 1.84 to 2.15), with peak occurring earlier (12 versus 84 hours). In vitro albumin-binding and animal data attributed this to competition for albumin at the injection site, with icodec outcompeting semaglutide. All products were well tolerated, though more gastrointestinal adverse events occurred with IcoSema than with either component alone. No glycaemic efficacy endpoints were assessed; no p values or ARR/NNT apply to this pharmacokinetic design. |
Expert Commentary
This is a clean single-dose pharmacokinetic study, and its verdict should be read narrowly: co-formulating icodec and semaglutide into IcoSema does not alter the total exposure of either drug, but it nearly doubles the semaglutide peak concentration and brings that peak forward by roughly three days. The mechanistic explanation, competition for injection-site albumin binding with icodec winning out, is internally coherent and supported by the in vitro and animal data presented. What this study does not show must be stated plainly: there are no glycaemic, weight, or clinical safety outcomes here, so nothing about efficacy can be inferred. The most weighable limitation is that this is a small, single-dose, manufacturer-sponsored pharmacokinetic experiment in 31 carefully selected participants with near-target HbA1c; steady-state behaviour after repeated weekly dosing, and whether the higher early semaglutide peak translates into more nausea or different glycaemic effects in practice, remain open. Can I use this with my patients? Not yet. IcoSema is not an approved, prescribable product on the basis of this work, and these data exist mainly to justify the fixed-ratio dose selection that downstream efficacy and safety trials will test. Clinicians should watch the phase 3 IcoSema programme for hard endpoints, and interpret the doubled semaglutide peak as a dosing-design signal rather than a clinical advantage.
References
Westergaard L, Alifrangis L, Buckley ST, Coester HV, Klitgaard T, Kristensen NR, et al. Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus. Clin Drug Investig. 2024;44(11):849-861. doi:10.1007/s40261-024-01405-8
